Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00231153 · ClinicalTrials.gov registry record · Phase 3
Study of Omiganan 1% Gel in Preventing Catheter Infections/Colonization in Patients With Central Venous Catheters
A Phase 3 study, sponsored by Cadence Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,859
- Enrollment target
NCT00231153 is a Phase 3 study that has completed, run by Cadence Pharmaceuticals. The registered enrollment target is 1,859 participants.
The verdict
NCT00231153, a Phase 3 study, has completed, sponsored by Cadence Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,859 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether treatment with topical omiganan is more effective than treatment with topical povidone-iodine in preventing local catheter site infections and catheter colonization in patients who have central venous catheters.
Interventions
- DRUG Povidone-Iodine 10%
- DRUG Omiganan 1% gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,859 participants |
| Start Date | 2005-08 |
| Est. Completion | 2008-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00231153
The ClinicalTrials.gov registry entry for NCT00231153 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,859 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cadence Pharmaceuticals, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Povidone-Iodine 10% is the first listed.
NCT00231153 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00231153 about?
NCT00231153 is a clinical study titled "Study of Omiganan 1% Gel in Preventing Catheter Infections/Colonization in Patients With Central Venous Catheters". The purpose of this study is to determine whether treatment with topical omiganan is more effective than treatment with topical povidone-iodine in preventing local catheter site infections and catheter colonization in patients who have central venous catheters.
What is the current status of trial NCT00231153?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,859 participants. The study started on 2005-08. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00231153?
The interventions under investigation include: Povidone-Iodine 10% (DRUG), Omiganan 1% gel (DRUG).
Who is sponsoring clinical trial NCT00231153?
This trial is sponsored by Cadence Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.